

Filed: November 19, 2025

On behalf of **Dr. Falk Pharma GmbH**

By: Nathanael Luman (Reg. No. 63,160)
Eric S. Furman (Reg. No. 45,664)
Jared C. Bunker (Reg. No. 58,474)
KNOBBE, MARTENS, OLSON & BEAR, LLP
3579 Valley Centre Drive, Suite 300
San Diego, CA 92130
Ph: 949-760-0404
Email: BoxFalkPharma@knobbe.com

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. FALK PHARMA GMBH,
Petitioner

v.

ELLODI PHARMACEUTICALS, L.P.,
Patent Owner

Case No. IPR2025-00056
Patent No. 11,260,061

PETITIONER'S UPDATED EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Petitioner Dr. Falk Pharma GmbH (“Dr. Falk”) provides an updated list of its exhibits in this proceeding.

Exhibit No.	Description
1001	U.S. Patent No. 11,260,061 to Gosselin et al.
1002	U.S. Publication No. 20070111978 to Dohil et al. (“Dohil”)
1003	RESERVED
1004	RESERVED
1005	“Guidance for Industry: Orally Disintegrating Tablets,” U.S. Food & Drug Administration, Center for Drug Evaluation and Research (CDER), 2008.
1006	Notice of Publication of FDA Guidance for Industry on Orally Disintegrating Tablets, Federal Register, Vol. 73, No. 242 at 76366, December 16, 2008.
1007	RESERVED
1008	RESERVED
1009	Svoboda et al., “Oral formulations of budesonide: a novel treatment for inflammatory bowel disease,” <i>Drugs of Today</i> , 44:857-863 (2008) at 857.
1010	Tan et al., “Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets,” <i>European Journal of Gastroenterology & Hepatology</i> , 13:425-427 (2001)
1011	Kolkman et al., “Evaluation of oral budesonide in the treatment of active distal ulcerative colitis,” <i>Drugs of Today</i> , 40:589-601 (2004)
1012	Siewert et al., “Eosinophilic gastroenteritis with severe protein-losing enteropathy: Successful treatment with budesonide,” <i>Digestive and Liver Disease</i> , 38:55-59 (2006)

Exhibit No.	Description
1013	Elsing et al., “Budesonide for the treatment of obstructive eosinophilic jejunitis,” Z. Gastroenterology, 45:187-189 (2007).
1014	Aceves et al., “Topical viscous budesonide suspension for treatment of eosinophilic esophagitis,” Journal of Allergy and Clinical Immunology 116:705-706 (2005)
1015	Aceves et al., “Oral Viscous Budesonide: A potential new therapy for eosinophilic esophagitis in children,” American Journal of Gastroenterology, 102:1-9 (2007)
1016	The United States Pharmacopeia, USP 32, 2009 at pages 262-263 “<701> Disintegration”
1017	Danckwerts, “Intraoral Drug Delivery: A Comparative Review,” American Journal of Drug Delivery, 1:171-186 (2003).
1018	Fu et al., “Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies,” Critical Reviews in Therapeutic Drug Carrier Systems, 21:433-475 (2004)
1019	Shukla et al., “Mouth Dissolving Tablets I: An overview of formulation technology,” Scientia Pharmaceutica, 77:309-326 (2009) (March 6, 2009)
1020	U.S. Publication No. 20050232988 to Venkatesh et al.
1021	RESERVED
1022	RESERVED
1023	RESERVED
1024	RESERVED
1025	Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 11th edition, eds. Brunton, Lazo, Parker, 2005
1026	Budenofalk® Brochure (2005)

Exhibit No.	Description
1027	Budenofalk® Advertisement (2007)
1028	Dr. Falk Pharma Brochure (2008)
1029	<i>Curriculum Vitae</i> of Alan F. Parr, Pharm.D., Ph.D.
1030	RESERVED
1031	RESERVED
1032	RESERVED
1033	RESERVED
1034	RESERVED
1035	RESERVED
1036	RESERVED
1037	RESERVED
1038	RESERVED
1039	RESERVED
1040	RESERVED
1041	Conway, “Solid dosage forms,” Chapter 4.1 in <i>Pharmaceutical Manufacturing Handbook: Production and Processes</i> , ed. Gad, pages 235-265 (2008)
1042	RESERVED
1043	RESERVED
1044	RESERVED
1045	RESERVED
1046	RESERVED

Exhibit No.	Description
1047	RESERVED
1048	RESERVED
1049	RESERVED
1050	RESERVED
1051	RESERVED
1052	RESERVED
1053	RESERVED
1054	Wen, “Adsorption at solid surfaces: pharmaceutical applications,” in Encyclopedia of Pharmaceutical Technology, Third Edition, ed. Swarbrick, pages 34-45 (2007)
1055	Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences, Fourth Edition, eds. Martin et al. (1993)
1056	Prosecution history excerpts from U.S. Application No. 17/211,119, which issued as U.S. Patent No. 11,260,061
1057	U.S. Publication No. 2011/0081411 to Perrett et al.
1058	U.S. Publication No. 2009/0191275 to Dohil et al. (“Dohil2009”)
1059	Redline comparison of Dohil and Dohil2009
1060	McGraw-Hill Dictionary of Scientific and Technical Terms, Sixth Edition (2003), “Adsorption”
1061	EP3041476B1
1062	The Opposition Division of the European Patent Office decision regarding EP3041476
1063	International Publication No. WO2011041509

Exhibit No.	Description
1064	Roeder et al., “Safety and efficacy of fluticasone propionate in the topical treatment of skin diseases,” <i>Skin Pharmacology Physiology</i> , 18:3-11 (2004)
1065	Remedios et al., “Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate,” <i>Gastrointestinal Endoscopy</i> , 63:3-12 (2006)
1066	Konikoff et al., “A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis,” <i>Gastroenterology</i> , 131:1381-1391 (2006)
1067	Khan et al., “An approach for rapid disintegrating tablet: a review,” <i>Int’l J. Pharm. Research and Development</i> , 21:170-183 (2011)
1068	Prosecution history excerpts from U.S. Application No. 14/917,125, which issued as U.S. Patent No. 10,471,071
1069	“Cellulose, Silicified Microcrystalline,” <i>Handbook of Pharmaceutical Excipients</i> , 5th edition, eds. Rowe et al., pages 139-141 (2006)
1070	Declaration of Alan F. Parr, Pharm.D., Ph.D. regarding U.S. 11,260,061
1071-1113	RESERVED
1114	November 3, 2025 Oral Hearing Transcript Regarding IPR2025-00052, IPR2025-00054, IPR2025-00055, and IPR2025-00056

Respectfully submitted,

Dated: November 19, 2025

By: /Nathanael R. Luman/

Nathanael R. Luman (Reg. No. 63,160)
KNOBBE MARTENS OLSON & BEAR, LLP

Attorney for Petitioner Dr. Falk Pharma GmbH

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on the date below a copy of **PETITIONER'S UPDATED EXHIBIT LIST AND EXHIBIT 1114** was served by email to counsel for Ellodi at addresses below:

Sanya Sukduang
ssukduang@cooley.com

Jonathan Davies
jdavies@cooley.com

Jonathan Cousin
jcousin@cooley.com

Isha Agarwal
iagarwal@cooley.com

Ellodi_IPR@cooley.com

Dated: November 19, 2025

By: /Nathanael R. Luman/

Nathanael R. Luman (Reg. No. 63,160)
KNOBBE MARTENS OLSON & BEAR, LLP